DOV has three compounds currently in preclinical development for the treatment of central nervous system disorders.
- The first, DOV 22,047, is believed to act at a specific GABAA receptor subtype and is under development for the treatment of panic disorder.
- The second, DOV 21,947, is structurally related to DOV 216,303 and is a triple uptake inhibitor under development to treat depression.
- The third, DOV 102,677, is a selective dopamine uptake inhibitor that may be used in the treatment of attention deficit disorder and Parkinsons disease.
Additionally, DOV is evaluating bicifadine and DOV 102,177, a structurally related molecule, in preclinical studies for stress incontinence.
